Abstract
Introduction

Structure, expression and function of Fas and Fas ligand
"Death receptor" is a term for members of the tumor necrosis factor (TNF) family of receptors responsible for the execution of the extrinsic apoptotic pathway and characterized by an intracellular α-helical protein-protein interaction domain named the death domain (DD). Eight members of the group have been described so far, including a prototypical death receptor Fas (FS-7-associated surface antigen; CD95; APO1; TNF receptor superfamily member 6, TNFRSF6).
Fas is a type I transmembrane protein expressed by numerous healthy and tumor cells and tissues, including B and T lymphocytes, dendritic cells, thymocytes, macrophages, cardiomyocytes, hepatocytes, and various cells within the kidney, pancreas, and brain (1-3).
The extracellular portion of the Fas protein comprises three cystein-rich domains characteristic for the TNF superfamily, while the intracellular portion includes the aforementioned death domain (4) . A splicing variant of Fas lacks the transmembrane domain and is consequently shed as a soluble receptor, the form that probably has some regulatory functions, competing with membrane-bound Fas for Fas ligand (5) .
Fas is specifically activated by its ligand -Fas ligand (CD178; CD95L; APO1L; TNF ligand superfamily member 6, TNFSF6), a type II protein (6, 7) . The expression of Fas ligand is more restricted, particularly to lymphocytes T (mainly CD8+ but also some CD4+) and natural killer (NK) cells (8) . It is worth mentioning that Fas ligand is also substantially expressed by immunologically privileged tissues such as the eye, testis, and placenta (9) .
The primary or the most biologically active form of Fas ligand is a trimer on the cell surface but two other forms have also been documented. The extracellular, TNF-homologous domain of Fas ligand can be cleaved from the membrane by metalloproteinases, thus resulting in a secreted trimer, which seems to be functionally quite inert and could have a regulatory role by occupying the binding sites on Fas (10) . Furthermore, Fas ligand can also be secreted as membrane-bound, in a form of specific microvesicles, which are thought to be biologically active although their exact role is still not quite clear (11) . Although the main receptor of Fas ligand is Fas, the decoy receptor 3 (DcR3), another member of the TNF receptor superfamily, is also able to bind Fas ligand, thus functioning as a regulator of the Fas-Fas ligand pathway (12) . Interestingly, there are reports showing that Fas ligand per se can act as a receptor by reverse signaling through its intracellular tail (13) .
The first step of the Fas intracellular signaling pathway is the trimerization of Fas within the lipid rafts (14) . Trimers of Fas-Fas ligand are subsequently oligomerized, which brings the intracellular parts of the Fas receptor in close proximity. This clustering triggers downstream signaling ( Fig. 1) : the DD of Fas binds a small adapter molecule, Fas-associated death domain (FADD) (15) . FADD is characterized by the death effector domain (DED) which, through homotypic interactions, recruits pro-caspase-8 and pro-caspase-10, forming a death-inducing signaling complex (DISC), the molecular platform for initiation of Fas-mediated events (16) .
The formation of DISC results in autoproteolytic activation of caspase-8, and formation of an active caspase-8 heterotetramer which is released into the cytosol to activate the effector caspase-3 (17) . Besides aforementioned, there are additional molecules which have been described to recruit to DISC (i.e. DAXX, FAP-1, FLASH, RIP, FAF-1), but their precise roles still need to be elucidated (18) . DISC formation is an important regulatory instance of the Fas pathway where processing of procaspase-8 can be blocked by c-FLIP (cellular FLICE [=caspase-8, FADD-like interleukin-1β-converting enzyme] inhibitory protein), which interacts with FADD through DED (18) . FADD can also bind to a transmembrane protein TOSO, another anti-apoptotic factor (19).
Subsequent intracellular events are the basis for the classification of cells in two types with respect to the involvement of the mitochondrial (internal) pro-apoptotic machinery (18 (20) . The amounts of activated caspase-8 are relatively low, so the apoptotic signal needs to be amplified through the internal (mitochondrial) apoptotic pathway (17) .
The ability of Fas to mediate cell death is best observed in the immune system, where it contributes to the shutdown of chronic immune responses and to the maintenance of peripheral tolerance, by a process known as restimulation-induced cell death (RICD) (21) .
Within the course of a prolonged immune response the availability of growth factors as well as diminished stimulation by antigen receptors make T and B cells susceptible to various apoptotic stimuli (16) . Moreover, repeatedly stimulated cells upregulate their expression of Fas ligand (22) thus killing themselves (suicide) and neighboring T cells (fratricide) as well as B cells, dendritic cells, and macrophages (23, 24) . In addition to the lymphocyte homeostasis, Fas-Fas ligand is an executive mechanism used by the effector arm of the immune response to combat infections. Fas ligand is expressed by both CD8+ T cells and NK cells (25) and it contributes mostly to the killing of virus-infected cells (26) and possibly some tumor cells (27) . It is also worth to mention that CD4+ cells could suppress the CD8+ cells by the Fas pathway (28).
Although apoptosis is the most striking outcome of Fas -Fas ligand interaction, their biological effects not based on cell death should be emphasized. Fas/Fas ligand interaction increases the production of chemokines in NK-T cells (29) , increases also the activation of dendritic cells, and increases cellular proliferation (30) . Fas ligand is a pro-survival factor for human CD34+ cells (31) and augments their colony-forming capacity (32) .
Having in mind the various roles of the Fas-Fas ligand system, it is not surprising that its effects are not mediated only by the cells' apoptotic machinery but via other signaling pathways as well. The intracellular portion of Fas receptor contains a tyrosine-containing motif tyrosine-x-x-leucine, similar to the canonical immunoreceptor-tyrosine-activationmotifs (14) . Upon ligand binding a phosphatydilinositol-3-kinase (PI3)-activation complex (PAC) is formed, with subsequent phosphorylation of a number of intracellular targets (33) .
Although the functional consequences are still poorly understood, this pathway is caspase-8-independent, and does not lead to apoptosis but, at least in the model of a glioblastoma cell line, promotes cellular migration (14) . Increased motility and invasiveness of tumor cell lines have also been described as a result of Fas-mediated activation of nuclear factor (NF) κB pathway (34) . Depending on the subtle balance between procaspase-8 and c-FLIP at the DISC, engagement of Fas could lead to either caspase-mediated cell death, or triggering of NFκB signaling and cellular activation (35) . Caspases are also confirmed to cleave the components of the NFκB pathway, and thus, regulate cellular proliferation responses (36).
Finally, several groups reported on involvement of another major group of signaling molecules, i.e. mitogen activated protein kinases (MAPK) (37, 38) in Fas-mediated systems.
Involvement of Fas in osteoresorption
Expression and function of Fas on the cells of the skeletal system
Bone remodeling is a continuous process in which bone is resorbed by osteoclasts and formed by osteoblasts, to maintain bone mass. Osteoblasts develop from mesenchymal progenitors present in bone marrow as well as in various tissues such as trabecular bone, fat, synovium, 
Mouse models for studying the role of the Fas/Fas ligand system in osteoresorptive disorders
Biological function of Fas and Fas ligand as regulatory molecules in the immune system has been confirmed and extensively studied using mouse models with spontaneous or induced mutations.
There are two spontaneous mutation models for studying the Fas/Fas ligand system, and several induced mutations, i.e. knock-out models for either or both of the molecules. A spontaneous mutation in the coding for Fas ligand gene on chromosome 1 [a T-to-C transition point mutation that causes a replacement of a highly conserved phenylalanine with a leucine at position 273 in the extracellular region of the encoded protein (60)] has first been described in the C3H/HeJ strain (61) . Mice homozygous for this mutation are unable to express a fully functional Fas ligand and develop lymphadenopathy and systemic autoimmune disorder, typically with enlargement of all lymph nodes, spleen, and increased numbers of T and B lymphocytes and dysregulation of their maturation and function (62) . Due to their phenotype -generalized lymphoproliferative disorder -the mutant mice were named gld. A spontaneous mutation in the coding region of the Fas gene on chromosome 19 (63), first described in the MRL strain of mice (64) , presents as a disorder very similar to the gld phenotype called a lymphoproliferative syndrome or lpr. One of the characteristics of both models is the progressive accumulation of non-malignant CD4 -CD8 -T lymphocytes. Because of the similarities of the two phenotypes it has early been postulated that these genes represented a receptor-ligand pair (65) .
Although both of these point mutations lead to an abolishment of Fas ligand and Fas function, respectively, it has been shown that both mutations may be leaky. The leakiness of the lpr mutation was shown (66) because small amounts of intact mRNA for Fas were found in immunocompetent tissues of lpr mice (e.g. thymus), and the leakiness of the gld mutation was long suspected because the gld phenotype did not correspond well to that of the Fas knock-out mutant mice (67) . Hence, the introduction of knock-out strains (Fas-null mice by Adachi et al, and Fas ligand-null mice by Karray et al) helped to fully characterize the role of the system and the phenotype (68, 69) . The most striking differences in phenotypes of induced models with a complete lack in Fas/Fas ligand signaling compared to mutant models are in the level of lymphoproliferation and the involvement of the liver; although the phenotypes are strainspecific (e.g. the MRL strain shows the most severe phenotype).
As the largest part of the cells of the skeletal system undergo apoptosis -up to 80% of osteoblasts (51) , and most of osteoclasts (70), it has long been postulated that the Fas/Fas ligand system is involved in the regulation of, at least, some aspects of bone cell proliferation and cell death. As results of in vitro experiments on the expression and function of either molecule in cells of the skeletal system are often contradictory, mouse models lacking components of Fas/Fas ligand system have been used to study their regulatory effects on bone homeostasis. Since osteoresorptive disorders have a complex pathogenesis, involving several organ systems and multiple cellular interactions on various levels, studies on animal models of osteoresorption are necessary to confirm the physiological importance of a single molecule or molecular system in the pathogenic process. There are two widely used models for systemic and localized osteoresorption: 1) estrogen withdrawal by ovariectomy (ovx), and 2) murine arthritic disease accompanied by localized osteodestruction and systemic osteoresorption. Estrogens are important regulators of both the immune system (71) as well as bone (72) , and modification of levels of estrogen is an invaluable model for the analysis of the Fas/Fas ligand system (73) . It has been shown in vivo that the disregulation in the Fas/Fas ligand system protects bones from the effects of estrogen withdrawal (55, 74, 75) , i.e. bone loss. Joint destruction in arthritic diseases is a consequence of synovial hyperplasia which leads to formation of tissue-invasive pannus, increased osteoclastogenesis followed by localized bone resorption, and destruction of articular cartilage by inflammatory cells (76) .
Furthermore, hyperplastic synovia contains mesenchymal cells with a reduced ability to differentiate into mature mesenchymal lineage-cells (osteoblasts, chondroblasts, and adipocytes) (77) . Impaired mesenchymal differentiation may be responsible for decreased osteoblastogenesis and may also contribute to subchondral bone loss in arthritis. However, studied on in vivo models, the role of Fas/Fas ligand system in the arthritic joint destruction is controversial, and points to the influence of genetic factors on the pathogenesis of arthritis.
For example, the MRL-lpr mouse strain constitutively develops autoimmune arthritis in approximately 20% of animals (78) . On the other hand, it has been shown that collagen induced arthritis is less severe in C57BL/6 mice with an lpr mutation and that this finding cannot be explained by the suppression of immune responses (79) . Such differences can be also ascribed to the differences in cellular populations affected by Fas deficiency between different genetic backgrounds.
The role Fas ligand/Fas system in human diseases
Although the Fas/Fas ligand system has been recognized as one of the key pathways in controlling the proliferation and cell death in many sites and tissues, human diseases involving mutations of components of this system are quite rare. These spontaneous mutations are described as an autoimmune lymphoproliferative syndrome (ALPS), and could be subdivided into four classes, with respect to the affected molecule (80) . The syndrome is characterized by lymphadenopathy and splenomegaly, which are most often accompanied by autoimmune hemolytic anemia, thrombocytopenia and other autoimmune manifestations (81) .
In addition, the Fas/Fas ligand system has also been shown to contribute to several human autoimmune diseases such as autoimmune thyroiditis, systemic lupus erithematosus, and rheumatoid arthritis (82) . Developing strategies to modulate these molecules for therapeutic purposes have become a promising challenge (83) (84) (85) .
Postmenopausal osteoporosis is the most common form of osteoporosis in which estrogen deficiency gives rise to an imbalanced high bone turnover, characterized by an enhanced osteoclast activity and a temporal increase in osteoblast activity which is not able to balance osteoclast-mediated bone resorption (86) . Although various systemic and local regulators are Similar to the animal models, the human studies also point to the still controversial role of the Fas/Fas ligand pathway in human disorders accompanied by osteoresorption, and caution is warranted in the use of Fas as a therapeutic target, as some patients with inflammatory arthritides may benefit from blockade, while others may benefit from agonism of Fas (95).
Therapeutic approaches to modulate Fas/Fas ligand pathway in osteoresorptive disorders
Osteoresorptive disorders develop when bone resorption by osteoclasts overcomes the bone formation by osteoblasts. Since Fas is shown to be expressed under various conditions on osteoblasts and osteoclasts, therapeutic approaches, both agonizing and antagonizing Fas signaling may be helpful in the treatment of osteoresorptive disorders, i.e. promoting Fas activation and apoptosis in osteoclasts, and inhibiting Fas mediated apoptosis in osteoblasts. As suggested by specific modulation of signaling pathways in tumors of tissue cells (18, 85, 104, 105) , tissue specific interventions directly aiming the Fas downstream signaling pathway, which is at the same time critical for osteoblast/osteoclast differentiation such as Raf/MEK/ERK, NF-κB and JNK/Jun, Wnt, and Smads, should be appreciated as more powerful and promising approaches (Fig. 2) .
Among the first were agonistic therapeutic interventions on Fas in arthritis, where hyperplastic synoviocytes destroy the subchondral bone. Since synovial inflammation is characterized by the unique resistance of proliferating synoviocytes to Fas-related apoptosis, Fas activation in these cells has drawn much attention as a possible tool to prevent joint destruction in both animal and human inflammatory arthritides (90) . In line with this idea is the study that investigated apoptosis resistance caused by defects in the extrinsic and intrinsic 
Conclusions
Fas is a member of the death receptor subgroup of the TNF receptor superfamily, activated Therapeutic inhibition, or in some cases, activation of Fas receptor may be a promising approach in these conditions. However systemic anti-Fas therapy has many complications and side effects, and therefore, new therapeutic approaches have to be established to modify the Fas/Fas ligand system in human diseases. These approaches include the use of systemic modulators which also affect expression and function of Fas, gene therapy or iRNA.
However, a more specific therapeutic approach would target Fas intracellular signaling molecules coupled with pathways involved in osteoblast or osteoclast differentiation and activity, and their identification is required to fulfill this goal.
Expert opinion
Fas receptor is ubiquitously expressed in human and animal tissues, including skeletal tissue Phase II clinical trials. This approach may also be beneficial in osteoresorptive disorders, through modifying the life span, differentiation, and activity of osteoblasts and osteoclasts.
These alternative molecular components connecting Fas signaling and osteoblast/osteoclast differentiation and activity are still undefined and their functional importance still requires stronger evidence from preclinical studies. A better understanding of these pathways will clarify additional molecular mechanisms leading to osteoresorption, and contribute to the definition of new therapeutic targets.
Article highlights
• Fas is a receptor from the TNF receptor superfamily, whose activation by binding of Fas ligand leads to apoptosis via external apoptotic pathway. Additionally, non-apoptotic effects of Fas signaling include regulation of cell proliferation, differentiation, and activation.
• Expression and function of Fas on bone forming osteoblasts and bone resorbing osteoclasts has been extensively studied in vitro, but various reports often provide conflicting data. Fas and Fas ligand are shown to be expressed at certain stages of osteoblast and osteoclast differentiation, and their expression may be modified by various cytokines. Therefore, the Fas/Fas ligand system may be directly involved in the regulation of bone homeostasis.
• Importance of Fas in osteoresorptive disorders has been confirmed in mice with loss-offunction mutation in Fas, by two animal models of osteoresorption: estrogen withdrawalinduced bone loss and collagen induced arthritis, a mouse model of human rheumatoid arthritis. These findings are in accordance with the results of several studies on postmenopausal osteoporosis and rheumatoid arthritis involving human subjects.
• Since bone loss is a result of shifting the balance between bone formation by osteoblasts and bone resorption by osteoclasts towards resorption, therapeutic approaches promoting Yellow arrows point to the components of osteoblast and osteoclast differentiation pathways, which are proposed to be regulated by Fas signaling.
